[1] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.[2] OKEDA R, SHIBUTANI M, MATSUO T, et al. Experimental neurotoxicity of 5 fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine[J]. Acta Neuropathol (Berl), 1990, 81(1): 66-73.[3] KUBOTA T. 5 fluorouracil and dihydropyrimidine dehydrogenase[J]. Int J Clin Oncol, 2003, 8(3): 127-131.[4] TERASHIMA M, IRINODA T, FUJIWARA H, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5 fluorouracil in human gastric cancer[J]. Anticancer Res, 2002, 22(2A): 761-768.[5] FAZZONE W, WILSON P M, LABONTE M J, et al. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells[J]. Int J Cancer, 2009, 125(2): 463-473.[6] KATO T, HANCOCK R L, MOHAMMADPOUR H, et al. Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice[J]. Cancer Lett, 2002, 187(1-2): 169-177.[7] BATHEN T F, HOLMGREN K, LUNDEMO A G, et al. Omega 3 fatty acids suppress growth of SW620 human colon cancer xenografts in nude mice[J]. Anticancer Res, 2008, 28(6A): 3717-3723.[8] DUPERTUIS Y M, MEGUID M M, PICHARD C. Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids[J]. Curr Opin Clin Nutr Metab Care, 2007, 10(4): 427-432.[9] WORKMAN P, ABOAGYE E O, BALKWILL F, et al. Guidelines for the welfare and use of animals in cancer research[J]. Br J Cancer, 2010, 102(11): 1555-1577.[10] CALVIELLO G, DI NICUOLO F, SERINI S, et al. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5 fluorouracil[J]. Cancer Chemother Pharmacol, 2005, 55(1): 12-20.[11] SOBOCANEC S, BALOG T, SARIC A, |